Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis
Stopped Sponsor terminated the study since a new molecular entity was able to achieve greater target coverage
Conditions
Interventions
- DRUG: Tilpisertib
- DRUG: Placebo
Sponsor
Gilead Sciences